Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744261 | 1.00 | USP30 (0.54) | USP30MAPK1BRD4ALDH1A1LMNA | |
| SCHEMBL18928570 | 0.94 | BRD4 (0.49) | USP30MAPK1BRD4ALDH1A1LMNA | |
| SCHEMBL28563880 | 0.94 | BRD4 (0.49) | USP30MAPK1BRD4ALDH1A1LMNA | |
| SCHEMBL16657349 | 0.89 | ALDH1A1 (0.46) | USP30MAPK1BRD4ALDH1A1LMNA | |
| SCHEMBL3998307 | 0.87 | ALDH1A1 (0.54) | USP30MAPK1BRD4ALDH1A1LMNA | |
| SCHEMBL30273843 | 0.87 | ALDH1A1 (0.54) | USP30MAPK1BRD4ALDH1A1LMNA | |
| SCHEMBL16896124 | 0.87 | USP30 (0.49) | USP30BRD4ALDH1A1LMNAMAPT | |
| SCHEMBL16791245 | 0.87 | USP30 (0.49) | USP30BRD4ALDH1A1LMNAMAPT | |
| SCHEMBL25273382 | 0.86 | FPR2 (0.47) | USP30MAPK1ALDH1A1LMNAMAPT | |
| SCHEMBL31437323 | 0.86 | MEN1 (0.56) | USP30ALDH1A1LMNAMAPTHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| EP-2673269-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-6946477-B2 | 3-Substituted piperidines comprising urea functionality, and methods of use thereof | SEPRACOR INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20030114436-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | AQUILA BRIAN M (US) | 2003-06-19 | — | — | US | disclosed |
| US-6476050-B2 | ANALGESICS; LIGANDS FOR VARIOUS CELLULAR RECEPTORS, INCLUDING OPIOID RECEPTORS, OTHER G-PROTEIN-COUPLED RECEPTORS AND ION CHANNELS | SEPRACOR, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20010056090-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | SEPRACOR INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001068604-A2 | 3-SUBSTITUTED PIPERIDINES COMPRISING UREA FUNCTIONALITY, AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | USP30 4273/4885MAPK1 71/4885BRD4 3799/4885 |
| US-20010056090-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | OPRM1, OPRL1, OPRK1 | USP30 568/4885MAPK1 3199/4885BRD4 1307/4885 |
| US-20030114436-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | OPRM1, OPRL1, OPRK1 | USP30 568/4885MAPK1 3199/4885BRD4 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.